CRISPR: Move Beyond Differences
By Charis Thompson,
Nature
| 06. 24. 2015
Untitled Document
This autumn, researchers and other experts will come together to discuss the scientific, ethical and policy issues associated with gene-editing research in humans. Plans for the international meeting were announced by the US National Academy of Sciences and the National Academy of Medicine after a study was published in which researchers used a gene-editing tool known as CRISPR to modify the genomes of non-viable human embryos1.
Whether this meeting and others like it, planned in the United States, can help to forge a path for gene editing that takes into account all the relevant needs and concerns will depend on what efforts are made to integrate the diverse perspectives of people with different expertise and values. A first step to such integration is understanding how different perspectives arise.
One division in cares and concerns seems at times to fall along stereotypical gender lines. This was powerfully demonstrated during a meeting in Atlanta, Georgia, last month on biotechnology and ethics. About 200 global thought leaders gathered at BEINGS 2015 to “reach consensus on the direction of biotechnology...
Related Articles
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...